Pacific RxTracts - June 2025

Authors

Pacific RxTracts

Files

Description

Articles:

• Atzumi Receives FDA Approval as First Nasal Powder DHE for Migraine Treatment
• IMAAVY: First and Only FDA-approved Neonatal Fc Receptor Inhibitor for gMG
• New Prophylactic Treatment Approved for Hemophilia A or B, With or Without Factor Inhibitors
• Cytisinicline: The Next Smoking Cessation Aid
• FDA Approves Dupilumab for the Management of Chronic Spontaneous Urticaria
• Study Shows Promise in Combining Behavioral Treatment with Phentermine
• Metformin for Osteoarthritis
• A New Direction in Atopic Dermatitis Treatment
• Orforglipron: A Potential Oral Alternative to Injectable GLP-1 Agonists
• Beyond GLP-1s: MariTide’s Dual Mechanism in Weight Loss Therapy
• Atrasentan Gains FDA Approval to Combat Proteinuria in Primary IgA Nephropathy
• Fluoroquinolones and Increased Risk of Suicide?
• Baloxavir Offers a Promising New Indication in Reducing Influenza Transmission
• First of its Kind Antibiotic Shows Promise in Treating Uncomplicated Gonorrhea
• Tavapadon: A Promising New Therapy for Parkinson’s Disease
• Possible Dementia Protective Method by Herpes Zoster Vaccine
• From Risk to Resolution: Mitigating Drug Interactions in Cancer Treatment
• Combination Therapy In HER-2 Positive Cancer Treatment

Publication Date

6-2025

Volume

22

Issue

7

Pages

9

Publisher

University of the Pacific

City

Stockton, CA

Disciplines

Medicine and Health Sciences | Pharmacy and Pharmaceutical Sciences

Recommended Citation

Pacific RxTracts, "Pacific RxTracts - June 2025" (2025). Pacific RxTracts. 7.
https://scholarlycommons.pacific.edu/rx-tracts/7